The group will start a pivotal trial of samuraciclib following promising second-line results.
ApexOnco Front Page
Recent articles
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Genmab acquires the Dutch biotech for $8bn.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
